It was approved for the treatment of myelofibrosis (a myeloproliferative neoplasm), polycythemia vera, and bone marrow cancer in 2011 by the FDA.315 The recently approved fedratinib is a selective JAK2 inhibitor and is used for myelofibrosis treatment in the clinic.316 Meanwhile, it has been reported that fedratinib also showed efficacy in the treatment of NSCLC in preclinical studies. Here, JAK2 is linked to myeloproliferative neoplasm.